The acquisition of immunohistochemistry services provider QualTek will augment Discovery's existing histopathology services, the company said.
The company also said that it has acquired Beijing-based food safety testing firm Meizheng Group. The deal is expected to expand PerkinElmer's food safety capabilities.
The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 89 percent year over year.
After the merger closes, the combined company will be split into four units focused on Cologuard, Oncotype Dx, international business, and pipeline efforts.
The firms are also partnering to develop molecular diagnostic assays and for the supply of enzymes and oligonucleotides required for manufacturing.
The UK Competition and Markets Authority said blocking the deal could prevent a "substantial lessening of competition" in the NGS market.
Under the amended agreement, Illumina will pay PacBio $6 million each month until the end of this year and more if the deal is extended into 2020.
Industry experts say a receptive market and investor interest in new technologies have spurred the increase in genomics tools and molecular diagnostics IPOs.
The company's goal is to serve what it sees as a massive but underaddressed target group: Asian women.
OncoCyte provided additional details about the history of the Razor test, its timeline for making it commercially available, and plans for a follow-on study.
A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.
Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.
Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.
In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.